Content has been sponsored & developed by Orion Pharma (UK) Ltd.
Nearly 300 million people are affected by asthma worldwide, and more than 300 million by chronic obstructive pulmonary disease (COPD), with the numbers projected to increase in the future.1,2 Inhaled therapy is the most common form of treatment due to its effectiveness. However, there is an increasing need to minimise the environmental impact of care across healthcare services, including national health organisations, device producers and the pharmaceutical industry. The detrimental impact of health care on environment and climate can be mitigated through minimising greenhouse gas (GHG) emissions and offsetting – creating carbon neutral care options also for asthma and COPD.2
Pressurised metered dose inhalers (pMDI’s) have a carbon footprint 10 to 37 times higher than that of Dry powder inhalers (DPI’s).3, 4 Replacing one in ten pMDI’s with environmentally friendly alternatives would reduce carbon dioxide equivalent emissions by 58 kt CO2e per year in the England alone, according to a paper published in the BMJ Open.5
PLAYING OUR PART AT ORION PHARMA
For Orion, the fight against climate change means concrete action to minimise greenhouse gas emissions across the supply chain and throughout our products’ lifecycle. To push climate action in the pharma industry, Orion Corporation is committed to reaching company wide carbon neutrality by 2030.
Orion Pharma (UK) Ltd are proud sponsors of the NPA’s Your Health, Your Pharmacy initiative.
1. Turner, R. M., DePietro, M., & Ding, B. (2018). Overlap of Asthma and Chronic Obstructive Pulmonary Disease in Patients in the United States: Analysis of Prevalence, Features, and Subtypes. JMIR public health and surveillance, 4(3), e60. Accessed 10th February 2022. https://doi.org/10.2196/publichealth.9930
2. United Nations Environment Programme. 2018. Medical and Chemicals Technical Options Committee. 2018 Assessment Report. Accessed 10th February 2022. https://ozone.unep.org/sites/default/files/2019-04/MCTOC-Assessment-Report-2018.pdf
3. Hillman, T. et al. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ 2013;346:f3359. Accessed 10th February 2022. https://www.ncbi.nlm.nih.gov/pubmed/23714412
4. Montreal protocol on substances that deplete the ozone layer. Medical and chemicals technical options committee. Assessment report 2018. Accessed 10th February 2022. https://ozone.unep.org/sites/default/files/2019-04/MCTOCAssessment-Report-2018.pdf
5. Wilkinson, A.J.K. et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open Assessment report 2019. Accessed 10th February 2022. https://bmjopen.bmj.com/content/bmjopen/9/10/e028763.full.pdf